The short version. Peptides sit in a regulatory category most buyers have never heard of and most sellers do not explain. To be compounded lawfully at a 503A pharmacy, a bulk substance generally needs to be on FDA’s 503A Bulks List. On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee reviewed seven nominated peptides and voted to recommend six of them for that list: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted against Emideltide. A favourable vote does not put a substance on the list. FDA still has to act, and until it does, a recommendation is a signal about the future rather than a permission in the present. Meanwhile one provider we read states plainly that sermorelin and PT-141 are the only two peptides it considers legally compoundable, and four of the five publish no price at all.
01 / 06Recommended is not listed, and that is the whole page
The 503A Bulks List is the register of bulk drug substances that compounding pharmacies may generally use when there is no approved product to work from. Getting onto it is a process: somebody nominates a substance, FDA evaluates it, the Pharmacy Compounding Advisory Committee holds a public meeting and votes, and then FDA decides.
The committee advises. It does not legislate. ⭐ So the sentence “PCAC recommended BPC-157” and the sentence “BPC-157 is on the 503A Bulks List” are not the same sentence, and in September 2026 only the first one is true. Any marketing that collapses the two is describing a hoped-for future as a present fact.
02 / 06What the July meeting actually decided
| Peptide | PCAC vote, 23 to 24 July 2026 | On the 503A Bulks List today |
|---|---|---|
| BPC-157 | recommended for addition | no, FDA action still required |
| KPV | recommended for addition | no, FDA action still required |
| TB-500 | recommended for addition | no, FDA action still required |
| MOTS-c | recommended for addition | no, FDA action still required |
| Epitalon | recommended for addition | no, FDA action still required |
| Semax | recommended for addition | no, FDA action still required |
| Emideltide | recommended against | no |
From FDA’s advisory committee calendar for the 23 to 24 July 2026 PCAC meeting and published legal analyses of the outcome, both cited below. BPC-157 had previously been placed in Category 2, meaning not eligible for 503A compounding, which is the position the July vote recommends changing.
⚠️ Read the right-hand column twice. Every row of it says the same thing. The vote was real, it was recent, and it changed nothing yet.
03 / 06The claim one provider makes, and why we are quoting it
Tactus Health states on its peptide page, in its own words, that sermorelin and PT-141 are “the only two FDA-compliant, legally compoundable peptides”, prescribed after consultation and labs.
We are quoting that rather than asserting it, because it is a provider’s characterisation of the law and not a government statement. ⭐ But it is the most useful sentence we found on any peptide page all year, for two reasons. It is specific enough to be checked, which almost nothing in this category is. And it is commercially inconvenient to the company saying it, because it rules out every other peptide they might otherwise sell you.
Set it beside the July vote and you have the honest picture: one seller draws the line at two peptides today, and a federal advisory committee has just recommended widening it to eight. Neither of those is the same as FDA having widened it.
04 / 06What the five publish
| Provider | Peptides named | Published price | What it says about status |
|---|---|---|---|
| Tactus Health | sermorelin, PT-141 | not published | calls these the only two legally compoundable peptides; requires consultation and labs |
 Ivy Rx | sermorelin | publishes a cost guide | pricing-focused; status not addressed on the page read |
 Strut Health | sermorelin, as an oral troche | not published for peptides | no FDA-approval statement found, consistent with its other categories |
 Hone Health | sermorelin protocols | not published for peptides | notes insurance rarely covers compounded medications |
 Defy Medical | sermorelin | not published | clinic model, labs separate |
Read from each provider’s own live pages on 22 September 2026. Tactus Health and Hone Health both refused automated requests and were read in an ordinary browser. Where a provider does not publish a figure on the pages we could reach, we say so rather than substituting an estimate.
Four of the five publish no peptide price. That is a stronger version of the same pattern we found on enclomiphene and on oral compounded formats: the less settled the regulatory ground, the less anyone publishes.
05 / 06How to check what you are being offered
Is it on the list, or recommended?
Ask directly. A clinic that answers “PCAC recommended it in July” has just told you it is not on the list, whether or not it meant to.
Which pharmacy compounds it?
Same question that matters everywhere in compounded medicine, and it is answerable. A named, state-licensed pharmacy can be looked up. An unnamed one cannot.
Are labs part of it?
Sermorelin acts on the growth-hormone axis. A provider prescribing it without baseline bloodwork is skipping the step that tells anyone whether it is warranted.
06 / 06What this means for your decision
If a clinic offers you BPC-157, TB-500 or any of the other four recommended peptides today, the honest position is that a federal committee has recommended them for compounding and FDA has not yet acted. That is worth knowing before you pay, and it is worth asking the clinic to state in writing rather than inferring from a marketing page.
If you are being offered sermorelin or PT-141, at least one provider in this market considers those the two that currently stand on solid ground, and says so publicly. Ask for the same statement from whoever is prescribing to you, ask which pharmacy prepares it, and ask what labs they want first. Three questions, all answerable, and the quality of the answers will tell you more than any price comparison on this page.
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.
- Buchanan Ingersoll & Rooney PC. FDA PCAC Recommends Six Peptides for the 503A Bulks List. The six-of-seven outcome and the fact that FDA action is still required.
- Frier Levitt. FDA PCAC Peptide Vote: What the 503A Recommendations Mean.
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Category structure, including Category 2.
- Tactus Health. Online peptide prescription. The quoted characterisation of sermorelin and PT-141, read in-browser 22 September 2026.
- Ivy Rx, sermorelin cost guide; Strut Health, struthealth.com; Hone Health, honehealth.com; Defy Medical, defymedical.com. All read 22 September 2026.
Is BPC-157 legal to compound in 2026?
Not yet. It had been placed in Category 2, meaning not eligible for 503A compounding. The Pharmacy Compounding Advisory Committee voted on 23 to 24 July 2026 to recommend adding it to the 503A Bulks List, but a recommendation does not place a substance on the list and FDA action is still required.
Which peptides did the committee recommend?
Six of the seven nominated: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted against Emideltide. None of the six is on the list as a result of that vote alone.
What does sermorelin cost?
Only one of the five providers we read publishes a peptide cost guide at all, and four publish no figure on the pages we could reach. Published market guides put it in a wide band, which is a sign that the price is set at consultation rather than on a pricing page.
Are sermorelin and PT-141 different from the other peptides?
One provider, Tactus Health, publicly describes them as the only two FDA-compliant, legally compoundable peptides. That is their characterisation rather than a government statement, and we quote it because it is specific, checkable, and commercially inconvenient to them.
What should I ask a peptide clinic?
Whether the substance is on the 503A Bulks List or merely recommended, which state-licensed pharmacy compounds it by name, and what baseline labs they require before prescribing. All three are answerable and the answers are informative either way.